[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-ischemic-stroke-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-ischemic-stroke-patients":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100615561","phase-4-low-dose-tenecteplase-for-acute-ischemic-stroke-treatment-in-aging-patients-100615561",false,"NCT07294209","Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients","Efficacy and Safety of Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients: A Prospective, Multicenter, Randomized Controlled Study","DATE-AGING","Inclusion Criteria:\n\n1. Age ≥ 70 years;\n2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS \\\u003C4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);\n3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;\n4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;\n5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;\n6. Informed consent from the patient or surrogate.\n\nExclusion Criteria:\n\n1. Imaging demonstrates multi-lobar infarction (hypodensity \\>1\u002F3 cerebral hemisphere);\n2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to\n\n   * Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)\n   * Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement\n   * Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) \\> 1.7 or Prothrombin time (PT)\\>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and\u002For PT above the upper limit of the local laboratory reference range\n   * Platelet count of below 100×10\\^9\u002F L\n   * Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)\n   * Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days\n   * Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm\n   * Neoplasm with increased haemorrhagic risk\n   * Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial\u002Fvenous malformations\n   * History of significant trauma or major surgery within the past 3 months.\n   * Any known disorder associated with a significant increased risk of bleeding\n3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fextradural hematoma, etc.);\n4. Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.22 mmol\u002FL;\n5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;\n6. Seizure at stroke onset;\n7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;\n8. Participation in other clinical trials within 3 months prior to screening;\n9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.","ALL","70 Years",{"count":20,"type":21},798,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.",[27],"Acute Ischemic Stroke Patients","RECRUITING","2026-06-21",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":32},"2025-12-19",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Southwest Hospital, China","OTHER",51,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100610730","a-comparison-of-cyclic-manual-direct-aspiration-thrombectomy-plunger-technique-vs-static-manual-direct-aspiration-thrombectomy-for-treatment-of-acute-large-vessel-occlusion-stroke-100610730","NCT07231380","A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke","Plunger Stroke Trial: A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke With the Raptor Aspiration Catheter","Plunger","Inclusion Criteria:\n\n\\- Acute ischemic stroke due to occlusion of the terminal ICA or M1 segment of the MCA, Treatment can be initiated within 24 hours of symptom onset, Age 18 years or older\n\nExclusion Criteria:\n\n* Evidence of acute intracranial hemorrhage prior to treatment, Failure to obtain informed consent","18 Years",{"count":51,"type":21},500,[53],"NA","This prospective, randomized controlled trial will compare two manual aspiration techniques for treating acute ischemic stroke due to large vessel occlusion: cyclic aspiration (Plunger technique) and static aspiration. Both techniques use FDA-approved devices (Raptor Aspiration Catheters and VacLok syringes) and are standard of care. Approximately 500 participants across 20 sites will be randomized to one of the two techniques. The primary endpoint is First Pass Effect (TICI 2c\u002F3 after first attempt), with secondary endpoints including overall recanalization and 90-day functional outcomes. Results will address a critical gap in optimizing aspiration thrombectomy techniques.",[27,56],"Large Vessel Occlusion",[58,56,59,60,61],"Acute Ischemic Stroke","Mechanical Aspiration Thrombectomy","Plunger Technique","Stroke Intervention","NOT_YET_RECRUITING","2026-05-15",{"date":65,"type":32},"2026-05-19",{"date":67,"type":21},"2026-07-01",{"date":69,"type":21},"2027-06-01",{"name":71,"class":39},"Vanderbilt University Medical Center",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100593040","prospective-randomized-observer-blinded-single-center-study-comparing-90-day-functional-outcome-in-patients-who-received-intravenous-propofol-infusion-versus-inhalational-sevoflurane-for-general-anesthesia-during-mechanical-thrombectomy-in-patients-who-suffered-from-acute-ischemic-stroke-100593040","NCT07001267","Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke","Inclusion Criteria:\n\n* \\>18 years Acute ischemic stroke requiring endovascular treatment.\n\nExclusion Criteria:\n\n* \\\u003C18 years\n* Pregnant patients\n* Patients with malignant hyperthermia\n* Allergies or any contraindications to either inhalational or intravenous agents\n* Patients already on intravenous anesthetic infusions\n* Prisoners\n* Students and employees",{"count":79,"type":21},120,[53],"This study is being done to compare outcomes after surgery for individuals who receive anesthesia through by inhaling medication and individuals who receive anesthesia intravenously by needle when experiencing treatment for their stroke. Currently very little is known about the outcomes for patients when comparing these two techniques of providing anesthesia during surgery. This study will provide information regarding outcomes that will help health care providers decide which technique will be better for patients",[27],[84,85],"Inhalation anesthesia","Intravenous anesthesia","2026-03-10",{"date":88,"type":32},"2026-03-12",{"date":90,"type":32},"2025-06-04",{"date":92,"type":21},"2027-12-31",{"name":94,"class":39},"University of Kansas Medical Center",1]